Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases

Masaaki Yamamoto, Toru Serizawa, Yasunori Sato, Takuya Kawabe, Yoshinori Higuchi, Osamu Nagano, Bierta E. Barfod, Junichi Ono, Hidetoshi Kasuya, Yoichi Urakawa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We tested the validity of two prognostic indices for stereotactic radiosurgically (SRS)-treated patients with brain metastases (BMs) from five major original cancer categories. The two indices are Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) and our Modified Recursive Partitioning Analysis (RPA). Forty-six hundred and eight BM patients underwent gamma knife SRS during the 1998-2011 period. Primary cancer categories were non-small cell lung cancer (NSCLC, 2827 patients), small cell lung cancer (SCLC, 460), gastro-intestinal cancer (GIC, 582), breast cancer (BC, 547) and renal cell cancer (RCC, 192). There were statistically significant survival differences among patients stratified into four groups based on the DS-GPA systems (p < 0.001) in all five original cancer categories. In the NSCLC category, there were statistically significant mean survival time (MST) differences (p < 0.001) among the four groups without overlapping of 95 % confidence intervals (CIs) between any two pairs of groups with the DS-GPA system. However, among the SCLC, GIC, BC and RCC categories, MST differences between some pairs of groups failed to reach statistical significance with this system. There were, however, statistically significant MST differences (p < 0.001) among the three groups without overlapping of 95 % CIs between any two pairs of groups with the Modified RPA system in all five categories. The DS-GPA system is applicable to our set of patients with NSCLC only. However, the Modified RPA system was shown to be applicable to patients with five primary cancer categories. This index should be considered when designing future clinical trials involving BM patients.

Original languageEnglish
Pages (from-to)327-335
Number of pages9
JournalJournal of Neuro-Oncology
Volume111
Issue number3
DOIs
Publication statusPublished - 2013 Feb 1
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Breast
Neoplasm Metastasis
Lung
Brain
Survival Rate
Neoplasms
Confidence Intervals
Intestinal Neoplasms
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Clinical Trials
Breast Neoplasms
Survival

Keywords

  • Brain metastases
  • Grading system
  • Prognosis
  • Radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases. / Yamamoto, Masaaki; Serizawa, Toru; Sato, Yasunori; Kawabe, Takuya; Higuchi, Yoshinori; Nagano, Osamu; Barfod, Bierta E.; Ono, Junichi; Kasuya, Hidetoshi; Urakawa, Yoichi.

In: Journal of Neuro-Oncology, Vol. 111, No. 3, 01.02.2013, p. 327-335.

Research output: Contribution to journalArticle

Yamamoto, Masaaki ; Serizawa, Toru ; Sato, Yasunori ; Kawabe, Takuya ; Higuchi, Yoshinori ; Nagano, Osamu ; Barfod, Bierta E. ; Ono, Junichi ; Kasuya, Hidetoshi ; Urakawa, Yoichi. / Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases. In: Journal of Neuro-Oncology. 2013 ; Vol. 111, No. 3. pp. 327-335.
@article{944bb4def1814abcbf010e4e8834245a,
title = "Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases",
abstract = "We tested the validity of two prognostic indices for stereotactic radiosurgically (SRS)-treated patients with brain metastases (BMs) from five major original cancer categories. The two indices are Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) and our Modified Recursive Partitioning Analysis (RPA). Forty-six hundred and eight BM patients underwent gamma knife SRS during the 1998-2011 period. Primary cancer categories were non-small cell lung cancer (NSCLC, 2827 patients), small cell lung cancer (SCLC, 460), gastro-intestinal cancer (GIC, 582), breast cancer (BC, 547) and renal cell cancer (RCC, 192). There were statistically significant survival differences among patients stratified into four groups based on the DS-GPA systems (p < 0.001) in all five original cancer categories. In the NSCLC category, there were statistically significant mean survival time (MST) differences (p < 0.001) among the four groups without overlapping of 95 {\%} confidence intervals (CIs) between any two pairs of groups with the DS-GPA system. However, among the SCLC, GIC, BC and RCC categories, MST differences between some pairs of groups failed to reach statistical significance with this system. There were, however, statistically significant MST differences (p < 0.001) among the three groups without overlapping of 95 {\%} CIs between any two pairs of groups with the Modified RPA system in all five categories. The DS-GPA system is applicable to our set of patients with NSCLC only. However, the Modified RPA system was shown to be applicable to patients with five primary cancer categories. This index should be considered when designing future clinical trials involving BM patients.",
keywords = "Brain metastases, Grading system, Prognosis, Radiosurgery",
author = "Masaaki Yamamoto and Toru Serizawa and Yasunori Sato and Takuya Kawabe and Yoshinori Higuchi and Osamu Nagano and Barfod, {Bierta E.} and Junichi Ono and Hidetoshi Kasuya and Yoichi Urakawa",
year = "2013",
month = "2",
day = "1",
doi = "10.1007/s11060-012-1019-9",
language = "English",
volume = "111",
pages = "327--335",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases

AU - Yamamoto, Masaaki

AU - Serizawa, Toru

AU - Sato, Yasunori

AU - Kawabe, Takuya

AU - Higuchi, Yoshinori

AU - Nagano, Osamu

AU - Barfod, Bierta E.

AU - Ono, Junichi

AU - Kasuya, Hidetoshi

AU - Urakawa, Yoichi

PY - 2013/2/1

Y1 - 2013/2/1

N2 - We tested the validity of two prognostic indices for stereotactic radiosurgically (SRS)-treated patients with brain metastases (BMs) from five major original cancer categories. The two indices are Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) and our Modified Recursive Partitioning Analysis (RPA). Forty-six hundred and eight BM patients underwent gamma knife SRS during the 1998-2011 period. Primary cancer categories were non-small cell lung cancer (NSCLC, 2827 patients), small cell lung cancer (SCLC, 460), gastro-intestinal cancer (GIC, 582), breast cancer (BC, 547) and renal cell cancer (RCC, 192). There were statistically significant survival differences among patients stratified into four groups based on the DS-GPA systems (p < 0.001) in all five original cancer categories. In the NSCLC category, there were statistically significant mean survival time (MST) differences (p < 0.001) among the four groups without overlapping of 95 % confidence intervals (CIs) between any two pairs of groups with the DS-GPA system. However, among the SCLC, GIC, BC and RCC categories, MST differences between some pairs of groups failed to reach statistical significance with this system. There were, however, statistically significant MST differences (p < 0.001) among the three groups without overlapping of 95 % CIs between any two pairs of groups with the Modified RPA system in all five categories. The DS-GPA system is applicable to our set of patients with NSCLC only. However, the Modified RPA system was shown to be applicable to patients with five primary cancer categories. This index should be considered when designing future clinical trials involving BM patients.

AB - We tested the validity of two prognostic indices for stereotactic radiosurgically (SRS)-treated patients with brain metastases (BMs) from five major original cancer categories. The two indices are Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) and our Modified Recursive Partitioning Analysis (RPA). Forty-six hundred and eight BM patients underwent gamma knife SRS during the 1998-2011 period. Primary cancer categories were non-small cell lung cancer (NSCLC, 2827 patients), small cell lung cancer (SCLC, 460), gastro-intestinal cancer (GIC, 582), breast cancer (BC, 547) and renal cell cancer (RCC, 192). There were statistically significant survival differences among patients stratified into four groups based on the DS-GPA systems (p < 0.001) in all five original cancer categories. In the NSCLC category, there were statistically significant mean survival time (MST) differences (p < 0.001) among the four groups without overlapping of 95 % confidence intervals (CIs) between any two pairs of groups with the DS-GPA system. However, among the SCLC, GIC, BC and RCC categories, MST differences between some pairs of groups failed to reach statistical significance with this system. There were, however, statistically significant MST differences (p < 0.001) among the three groups without overlapping of 95 % CIs between any two pairs of groups with the Modified RPA system in all five categories. The DS-GPA system is applicable to our set of patients with NSCLC only. However, the Modified RPA system was shown to be applicable to patients with five primary cancer categories. This index should be considered when designing future clinical trials involving BM patients.

KW - Brain metastases

KW - Grading system

KW - Prognosis

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84883856890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883856890&partnerID=8YFLogxK

U2 - 10.1007/s11060-012-1019-9

DO - 10.1007/s11060-012-1019-9

M3 - Article

VL - 111

SP - 327

EP - 335

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -